%0 Journal Article
%A Remde, H.
%A Schmidt-Pennington, L.
%A Reuter, M.
%A Landwehr, L-S
%A Jensen, M.
%A Lahner, H.
%A Kimpel, O.
%A Altieri, B.
%A Laubner, K.
%A Schreiner, J.
%A Bojunga, J.
%A Kircher, S.
%A Kunze, C. A.
%A Pohrt, A.
%A Teleanu, Maria-Veronica
%A Hübschmann, Daniel
%A Stenzinger, A.
%A Glimm, Hanno
%A Fröhling, Stefan
%A Fassnacht, M.
%A Mai, K.
%A Kroiss, M.
%T Outcome of Immunotherapy in Adrenocortical Carcinoma - A retrospective cohort study.
%J European journal of endocrinology
%V 188
%N 6
%@ 0001-5598
%C Bristol
%I BioScientifica Ltd.
%M DKFZ-2023-01083
%P 485-493
%D 2023
%Z 2023 Jun 7;188(6):485-493
%X Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a real-life setting.Retrospective cohort study of 54 patients with advanced ACC receiving ICI as compassionate use at six German reference centres between 2016 and 2022.Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAE) were assessed.In 52 patients surviving at least 4 weeks after initiation of ICI, ORR was 13.5
%K PD-L1 (Other)
%K adverse drug reaction (Other)
%K immune checkpoint inhibitor (Other)
%K mitotane (Other)
%K treatment (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37260092
%R 10.1093/ejendo/lvad054
%U https://inrepo02.dkfz.de/record/276386